Free Testosterone Calculation: How to Interpret Your TRT Lab Results

The direct answer

Free testosterone is the unbound, biologically active portion of testosterone in blood. Total testosterone measures everything in circulation, including hormone tightly bound to sex hormone-binding globulin (SHBG) that cannot readily act on tissue. Because SHBG concentration varies between men and changes with age, body composition, thyroid status, and liver function, two men can have an identical total testosterone reading and a meaningfully different free testosterone level. Direct laboratory measurement of free testosterone is technically difficult at the picogram-per-milliliter concentrations involved, so most clinicians rely on a calculated estimate (commonly the Vermeulen equation, using total testosterone, SHBG, and a standard albumin value) rather than a direct assay. This calculated value, not total testosterone in isolation, is the number that should drive a hypogonadism diagnosis or TRT dose decision when total testosterone sits near the lower reference boundary or when SHBG is abnormal.

This is the central, testable idea of this page: the useful question when reading a testosterone panel is not "is total testosterone normal," but "does the calculated free testosterone, read alongside SHBG and symptoms, actually match the clinical picture." A normal total testosterone with high SHBG can hide a functionally low free testosterone. A low-normal total testosterone with low SHBG can still reflect an adequate free fraction. Treating total testosterone as a stand-alone verdict is a common source of both missed diagnoses and unnecessary treatment.

What free testosterone is and why the total number alone is not enough

Testosterone circulates in three pools: tightly bound to SHBG (the largest fraction, and essentially unavailable to tissue), loosely bound to albumin (able to dissociate and become available at the tissue level), and free or unbound. The free and albumin-bound fractions together are sometimes called "bioavailable testosterone." Conditions that raise SHBG, such as aging, hyperthyroidism, and some liver conditions, can produce a normal total testosterone alongside a low free testosterone. Conditions that lower SHBG, such as obesity and insulin resistance, can do the reverse: a low-normal total testosterone with an adequate free fraction.

Direct immunoassays for free testosterone are widely available from commercial labs but are considered unreliable at the very low concentrations found in blood; equilibrium dialysis is the recognized reference method but is not offered by most routine labs. For this reason, professional guidance generally favors a calculated free testosterone over a direct immunoassay result when a clinical decision hinges on the free fraction. Verification note: the specific accuracy figures sometimes quoted for direct assays versus equilibrium dialysis should be checked against a current primary source before being repeated in patient-facing material; this draft avoids citing a specific accuracy percentage because the underlying reference could not be confirmed.

The Vermeulen equation, in plain terms

The Vermeulen equation estimates free testosterone from three inputs: total testosterone, SHBG, and albumin. Albumin is usually fixed at a standard population value (commonly cited as 4.3 g/dL) rather than measured individually, because albumin's binding effect on testosterone is weak and the assumption introduces little error for most patients. The equation uses published binding affinity constants for SHBG and albumin to solve for the free fraction.

In practice, a patient does not do this math by hand. A clinician or an online calculator (several validated implementations exist, including tools associated with the International Society for the Study of the Aging Male) takes total testosterone and SHBG as inputs and returns calculated free and bioavailable testosterone. Most U.S. labs report total testosterone in ng/dL; converting to nmol/L (roughly, dividing by 28.85) is required before using most calculators, since the underlying equation was derived in SI units.

The clinical point worth remembering: at the same total testosterone, a higher SHBG produces a lower calculated free testosterone, and a lower SHBG produces a higher one. This is why two men with an identical total testosterone reading can have very different symptoms and very different treatment needs, and why SHBG is not an optional add-on test when total testosterone sits near a decision threshold.

Total testosterone: what "normal" means and why timing matters

Guideline-based reference ranges for total testosterone in adult men generally place the lower boundary near 300 ng/dL and the upper boundary near 1,000 ng/dL, though individual laboratories publish somewhat different numbers depending on the reference population and assay used, and readers should check the range printed on their own lab report rather than assuming a single universal cutoff applies. A formal hypogonadism diagnosis is not made from a single low reading; professional guidance calls for two morning total testosterone measurements, ideally drawn a week or more apart, because testosterone secretion is episodic and assay results carry some variability.

Testosterone follows a diurnal pattern, peaking in the early morning and declining over the course of the day. Reference ranges assume a morning draw (roughly 7 to 11 a.m.); an afternoon sample can read lower purely due to timing and should not be used alone to diagnose or rule out hypogonadism.

On testosterone therapy, the timing of the blood draw relative to the last dose changes the number substantially. A trough level drawn immediately before the next scheduled injection reflects the lowest point of the cycle; a peak level drawn one to two days after injection reflects the highest point. Neither single value fully represents average exposure across the dosing interval. Many monitoring protocols use a trough draw as the standard, reproducible comparison point specifically because it is easier to time consistently than a mid-cycle sample.

Estradiol on TRT: why the assay type matters

Standard estradiol immunoassays were built and calibrated for the female concentration range, which is far higher than typical male concentrations. At the low concentrations found in men, standard immunoassays are prone to imprecision and false elevation. A sensitive assay using liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the method generally recommended for measuring estradiol in men, including men on testosterone therapy, because it remains accurate at the lower concentrations involved.

Exogenous testosterone is converted to estradiol by the aromatase enzyme, mainly in fat tissue, so estradiol commonly rises on TRT. Reported tolerance varies between individuals: some men have no symptoms at estradiol levels that produce breast tenderness, water retention, or mood changes in others. There is no single estradiol number that reliably predicts symptoms across all patients, and dose or aromatase-inhibitor decisions should weigh both the lab value and the presence of actual symptoms, not the number alone.

A separate and clinically important caution: driving estradiol too low, whether by aggressive aromatase-inhibitor use or otherwise, is associated in the literature with adverse effects on bone health in men. This is one reason routine, prophylactic aromatase-inhibitor use in asymptomatic men on TRT is not standard practice; most protocols reserve it for men with confirmed elevation on a sensitive assay and corresponding symptoms.

When ordering labs, it is worth specifically requesting a "sensitive" or LC-MS/MS estradiol test by name, since a standard order may default to the immunoassay version.

CBC and hematocrit: the erythrocytosis risk that needs a plan, not just a number

Testosterone stimulates red blood cell production, an effect that is dose-related and expected rather than idiosyncratic. This is one of the more consistently reproduced findings in testosterone research, including in placebo-controlled trials in older men (the Testosterone Trials, published in the New England Journal of Medicine), which found a measurable rise in hematocrit in the testosterone group compared with placebo over about a year of treatment. Verification note: this draft intentionally avoids repeating the specific percentage-point figures from that trial because the source citation supporting them in the prior version of this article could not be independently confirmed; a clinician preparing the reviewed version should pull the exact figures directly from the published trial report.

Elevated hematocrit matters because it increases blood viscosity and is a recognized cardiovascular safety concern on testosterone therapy. Most clinical protocols check a CBC at baseline, again a few months after starting or changing dose, and then periodically thereafter, with a general pattern of: monitor more closely as hematocrit rises toward the high-normal range, adjust dose or injection frequency (or consider phlebotomy) at moderately elevated levels, and hold therapy at clearly elevated levels until it normalizes. The exact numeric thresholds used for these steps vary somewhat between protocols and should be confirmed against the current version of the relevant clinical guideline rather than treated as fixed here.

Injection frequency affects this risk independent of total weekly dose: splitting the same weekly milligram total into more frequent, smaller injections produces a lower peak testosterone and is generally associated with a smaller rise in hematocrit than the same total dose given once weekly. Men with obstructive sleep apnea, chronic lung disease, or a baseline hematocrit already in the high-normal range are usually monitored more closely.

Lipids on TRT: a modest, dose-related effect, not a dominant safety signal

Testosterone therapy has been studied for its effect on lipid parameters, and the general pattern reported across trials is a modest reduction in total and LDL cholesterol alongside a modest reduction in HDL cholesterol, with effects that are statistically detectable but clinically small at typical replacement doses. These effects appear more pronounced at supraphysiologic doses and with certain oral formulations than with standard injectable or transdermal replacement.

The larger cardiovascular safety question, whether TRT itself increases heart attack or stroke risk, was addressed more directly by the TRAVERSE trial, a large randomized cardiovascular safety trial published in the New England Journal of Medicine in 2023, which did not find a significant increase in major adverse cardiovascular events with testosterone therapy compared with placebo in middle-aged and older men with hypogonadism and elevated cardiovascular risk. Verification note: the specific hazard ratio and confidence interval quoted in earlier drafts should be re-checked against the published trial report before being restated as an exact figure in the reviewed article.

A practical monitoring pattern most clinics use is a baseline fasting lipid panel, a recheck a few months after starting or changing therapy, and periodic rechecks thereafter, more frequently in men with pre-existing dyslipidemia or on statin therapy.

Other labs that belong in the picture

PSA. Testosterone does not initiate prostate cancer, but it can support the growth of an existing, undiagnosed cancer, which is why a baseline PSA before starting TRT and periodic rechecks afterward are standard practice, particularly in men over 40. A PSA rise that is unusually large relative to baseline, or any new prostate symptom, warrants a urology referral rather than reassurance.

LH and FSH. These pituitary hormones help classify hypogonadism as primary (testicular, with high LH/FSH) versus secondary (pituitary or hypothalamic, with low or inappropriately normal LH/FSH) at baseline. On TRT, exogenous testosterone suppresses LH toward zero, confirming that the therapy is doing what is expected physiologically; LH and FSH are not typically rechecked routinely once treatment starts unless fertility is a concern.

SHBG. Beyond its role in the Vermeulen calculation, tracking SHBG periodically explains changes in calculated free testosterone that would otherwise look confusing. SHBG commonly falls after starting TRT because testosterone suppresses hepatic SHBG production; a man who started with high SHBG can see his free testosterone rise meaningfully even without a large change in total testosterone.

CMP and TSH. A baseline comprehensive metabolic panel checks liver and kidney function before starting therapy, which matters more for oral testosterone formulations than for injectable or transdermal ones. A baseline TSH is useful because hypothyroidism produces a symptom picture that overlaps heavily with hypogonadism (fatigue, low libido, weight gain) and independently raises SHBG, which can lower free testosterone even when total testosterone looks normal.

What is established, what is plausible, and what is not established

Established: Free testosterone is the biologically active fraction, and it can diverge meaningfully from what total testosterone alone suggests when SHBG is abnormal. Calculated free testosterone using validated equations is an accepted clinical alternative to direct assay. Testosterone therapy raises hematocrit in a dose-related way and requires monitoring. A sensitive, mass-spectrometry-based estradiol assay is more accurate in men than a standard immunoassay. The largest dedicated cardiovascular safety trial to date did not find increased major cardiovascular events with testosterone therapy in men with elevated cardiovascular risk, over the trial's follow-up period.

Plausible but not settled by this evidence base: The exact numeric estradiol range associated with symptom improvement versus symptom onset, since tolerance varies by individual and was not established here by a controlled comparison. The precise degree to which injection frequency versus total dose drives hematocrit risk, which is supported by physiologic reasoning and observational patterns more than by a single definitive trial cited here.

Not established from this material: Any single "optimal" free testosterone number that applies uniformly across all men, ages, and symptom profiles. This page does not provide individualized dosing or diagnostic advice; a hypogonadism diagnosis and any treatment decision should be made by a clinician evaluating the full clinical picture, not from a calculator result alone.

When to seek urgent or same-week medical attention

Chest pain, shortness of breath, one-sided weakness, or symptoms of a blood clot (leg swelling, calf pain) in a man on testosterone therapy warrant emergency evaluation, not a routine lab order. A markedly elevated hematocrit found on routine labs should prompt a call to the prescribing clinician rather than waiting for the next scheduled visit. New urinary symptoms or a substantial PSA rise should prompt a urology referral rather than reassurance from a lab report alone.

A framework for reading your own free testosterone results

This is a starting framework for organizing a conversation with a prescribing clinician. It is not a diagnostic tool and does not replace clinical judgment, and the specific numeric thresholds a given clinic uses may differ from the general patterns below.

Step 1: Is the total testosterone reading trustworthy on its own?

• Was it drawn in the morning (roughly 7 to 11 a.m.)? If not, treat the result as provisional and repeat under correct timing before acting on it.
• If this is a pre-treatment diagnostic reading, has it been confirmed with a second morning draw at least a few days to a week later? A single low reading is not a diagnosis.

Step 2: Does SHBG change the interpretation?

• If SHBG is clearly above or below the lab's reference range, total testosterone alone should not be treated as the final word; ask whether a calculated free testosterone was obtained.
• If total testosterone sits near the lower boundary of normal and SHBG is elevated, a "normal" total testosterone may still coexist with a low functional (free) testosterone. This is the scenario where a free testosterone calculation adds the most clinical value.

Step 3: On TRT, does the trough timing match the report?

• Compare the draw timing (trough versus peak versus mid-cycle) against what the clinic intended before comparing the number to a target range. A trough value and a peak value from the same regimen can differ substantially and are not interchangeable.

Step 4: Do the safety labs support continuing at the current dose?

• Hematocrit trending toward the high end of normal, a large PSA increase relative to baseline, or new dyslipidemia are reasons to bring dose, frequency, or route back into the conversation with the prescriber, rather than adjusting independently.

Step 5: Does estradiol explain the symptoms, or is it a red herring?

• An elevated estradiol on a sensitive assay in a symptomatic patient is a reasonable basis for discussing dose or frequency changes. An elevated estradiol in an asymptomatic patient is not, by itself, a strong reason to start an aromatase inhibitor, given the bone-health tradeoff of driving estradiol too low.

When to escalate beyond routine follow-up: new cardiovascular symptoms, hematocrit clearly above the clinic's stated action threshold, a substantial PSA rise, or estradiol-related symptoms that are worsening despite dose adjustment. These situations call for a clinician visit sooner than the next scheduled recheck, not a repeat home order.

Evidence and verification notes for the reviewing clinician

This draft removed several precise numeric claims and inline citations that appeared in the prior version of this article because the specific source identifiers attached to them could not be independently verified against the claims they were supporting. Before publication, a qualified reviewer should confirm and, where accurate, restore exact figures for: the Testosterone Trials hematocrit change, the TRAVERSE trial hazard ratio and confidence interval, the meta-analysis lipid effect sizes, and the direct-assay-versus-equilibrium-dialysis accuracy comparison, each against its original publication rather than a secondary description.

General sources referenced by name in this draft (identifiers not independently verified for this revision and should be confirmed before citing with a specific link):

• Endocrine Society, 2018 Clinical Practice Guideline on Testosterone Therapy in Men With Hypogonadism
• Testosterone Trials (TTrials), reported in the New England Journal of Medicine
• TRAVERSE cardiovascular safety trial, New England Journal of Medicine, 2023
• Vermeulen et al., original description of the calculated free testosterone method, Journal of Clinical Endocrinology and Metabolism, 1999

This article does not provide an individualized diagnosis, dosing recommendation, or treatment plan. Lab interpretation and TRT dosing decisions should be made with a licensed clinician who can review the complete history, examination, and full panel of results together.